Salarius Pharmaceuticals, Inc. (SLRX)
| Market Cap | 12.63M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -18.67M |
| Shares Out | 56.12M |
| EPS (ttm) | -0.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 50,952 |
| Open | 0.225 |
| Previous Close | 0.225 |
| Day's Range | 0.222 - 0.230 |
| 52-Week Range | 0.160 - 1.200 |
| Beta | 1.37 |
| Analysts | Buy |
| Price Target | 5.10 (+2,166.7%) |
| Earnings Date | Aug 5, 2022 |
About SLRX
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect... [Read more...]
Financial Performance
In 2021, SLRX's revenue was $1.84 million, a decrease of -64.84% compared to the previous year's $5.23 million. Losses were -$12.77 million, 73.7% more than in 2020.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for SLRX stock is "Buy." The 12-month stock price forecast is 5.1, which is an increase of 2,166.67% from the latest price.
News
Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Multiple development and data milestones expected from seclidemstat and SP-3164 programs in 2H22 Conference call and webcast today at 11:00 a.m. ET Multiple development and data milestones expected from...
Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ong...
Clinical Trial Now Expands to Fifteen U.S. Trial Sites Clinical Trial Now Expands to Fifteen U.S. Trial Sites
Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement
HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatmen...
Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday,...
Conference Call and Live Audio Webcast Scheduled for 11:00 a.m. ET Conference Call and Live Audio Webcast Scheduled for 11:00 a.m. ET
Salarius Pharmaceuticals to Participate in BIO International Convention 2022
HOUSTON, Texas, June 09, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatme...
Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatr...
Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results
Salarius Successfully Completes SP-3164 Pre-IND Meeting Process with FDA
Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug A...
Salarius planning for SP-3164 IND Application Submission in 2023 Salarius planning for SP-3164 IND Application Submission in 2023
Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress
Conference Call and Live Audio Webcast Scheduled for Thursday, May 12, 2022, 5:00 p.m. ET Conference Call and Live Audio Webcast Scheduled for Thursday, May 12, 2022, 5:00 p.m. ET
Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering
HOUSTON, April 22, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment op...
Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2021 Financial Results
Strategic acquisition of SP-3164, a targeted protein degrader in development for hematologic and solid tumors, adds to pipeline of cancer therapies
Insiders Buying These 4 Penny Stocks
US stock futures traded lower this morning after the Dow Jones gained more than 650 points on Wednesday. Investors, meanwhile, focused on some notable insider trades When insiders purchase or sell share...
Salarius Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results and Highlight Recent Company P...
Conference Call and Live Audio Webcast Scheduled for Thursday, March 10, 2022, 5:00 p.m. ET Conference Call and Live Audio Webcast Scheduled for Thursday, March 10, 2022, 5:00 p.m. ET
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference
HOUSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediat...
Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program
Dr. Santiesteban will lead the development of SP-3164 and other targeted protein degradation assets Dr. Santiesteban will lead the development of SP-3164 and other targeted protein degradation assets
Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Port...
Conference call and live audio webcast scheduled for today at 8:30 a.m. EST Conference call and live audio webcast scheduled for today at 8:30 a.m. EST
Salarius Pharmaceuticals to Present at Virtual H.C. Wainwright BioConnect, Participate in Virtual Biotech Showcase an...
HOUSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors,...
Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial
Ewing sarcoma arm advances to second lead-in safety dosing cohort in Sarcoma trial evaluating seclidemstat in combination with chemotherapy agents in patients with relapsed/refractory Ewing sarcoma and ...
Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum
HOUSTON, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediat...
Salarius Pharmaceuticals to Participate in Annual Benchmark Company Discovery One-on-One Conference
HOUSTON, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediat...
Salarius (SLRX) Reports Q3 Loss, Misses Revenue Estimates
Salarius (SLRX) delivered earnings and revenue surprises of 11.11% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Salarius Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress
Cash and Cash Equivalents of $31.9 Million Sufficient to Fund Completion of Ongoing Clinical Trials for Lead Drug Candidate Seclidemstat
Will Salarius (SLRX) Report Negative Earnings Next Week? What You Should Know
Salarius (SLRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Salarius Pharmaceuticals to Report Third Quarter 2021 Financial Results and Highlight Recent Company Progress
Conference Call and Live Audio Webcast Scheduled for Thursday, November 4, 2021, 5:00 p.m. ET Conference Call and Live Audio Webcast Scheduled for Thursday, November 4, 2021, 5:00 p.m. ET
Salarius Pharmaceuticals and Nationwide Children's Hospital Disclose Research Findings from Presentation at 2021 AACR...
HOUSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancer...